GB202109503D0 - Method - Google Patents

Method

Info

Publication number
GB202109503D0
GB202109503D0 GBGB2109503.9A GB202109503A GB202109503D0 GB 202109503 D0 GB202109503 D0 GB 202109503D0 GB 202109503 A GB202109503 A GB 202109503A GB 202109503 D0 GB202109503 D0 GB 202109503D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2109503.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurochase Innovations Ltd
Original Assignee
Xced LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xced LLP filed Critical Xced LLP
Priority to GBGB2109503.9A priority Critical patent/GB202109503D0/en
Publication of GB202109503D0 publication Critical patent/GB202109503D0/en
Priority to PCT/GB2022/051690 priority patent/WO2023275558A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
GBGB2109503.9A 2021-07-01 2021-07-01 Method Ceased GB202109503D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2109503.9A GB202109503D0 (en) 2021-07-01 2021-07-01 Method
PCT/GB2022/051690 WO2023275558A1 (en) 2021-07-01 2022-06-30 Delivery of gene therapies into muscle via the central nervous system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2109503.9A GB202109503D0 (en) 2021-07-01 2021-07-01 Method

Publications (1)

Publication Number Publication Date
GB202109503D0 true GB202109503D0 (en) 2021-08-18

Family

ID=77274420

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2109503.9A Ceased GB202109503D0 (en) 2021-07-01 2021-07-01 Method

Country Status (2)

Country Link
GB (1) GB202109503D0 (en)
WO (1) WO2023275558A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205772D0 (en) 2002-03-12 2002-04-24 Gill Steven S Catheter
GB0623395D0 (en) 2006-11-23 2007-01-03 Renishaw Plc Port
GB201002370D0 (en) 2010-02-12 2010-03-31 Renishaw Ireland Ltd Percutaneous drug delivery apparatus
GB201308917D0 (en) 2013-05-17 2013-07-03 Renishaw Plc Delivery

Also Published As

Publication number Publication date
WO2023275558A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
GB202010104D0 (en) Method
GB202100827D0 (en) Method
GB202004944D0 (en) Method
GB202004863D0 (en) Method
GB202015993D0 (en) Method
GB202014709D0 (en) Method
GB202014432D0 (en) Method
GB202011823D0 (en) Method
GB202010922D0 (en) Method
GB202010046D0 (en) Method
GB202007044D0 (en) Method
GB202006047D0 (en) Method
GB202004515D0 (en) Method
GB202003580D0 (en) Method
GB202109503D0 (en) Method
GB202101188D0 (en) Method
GB202100365D0 (en) Method
GB202020183D0 (en) Method
GB202020180D0 (en) Method
GB202018514D0 (en) Method
GB202018262D0 (en) Method
GB202018125D0 (en) Method
GB202017861D0 (en) Method
GB202017725D0 (en) Method
GB202016334D0 (en) Method

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: NEUROCHASE INNOVATIONS LTD

Free format text: FORMER OWNER: XCED LLP

AT Applications terminated before publication under section 16(1)